相关实验视频

Updated: Sep 17, 2025

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

通过加载Rapamycin的PLGA纳米颗粒来制mTOR通路的向抑制,用于增强膀癌治疗

Nour-Elhoda El-Hefnawy¹, Magdy M Youssef¹, Hassan Abol-Enein²

¹Department of Chemistry, Biochemistry Division, Faculty of Science, Mansoura University, Mansoura, Egypt.

Scientific reports

|July 3, 2025

概括

装有拉帕米辛 (Rapa-PLGA NPs) 的多 (乳糖-co-葡萄糖酸) 纳米颗粒显示出对膀癌治疗的前景. 这些纳米粒子增强药物输送,减少癌细胞生长和迁移,并通过调节基因表达来克服药物耐药性.

科学领域:

在瘤学瘤学.
纳米技术纳米技术
药理学药理学是指药理学的学科.

背景情况:

膀癌由于高复发率和耐药性而带来了重大挑战.
在膀癌中,PI3K/AKT/mTOR通路经常受到失调,这使其成为治疗点.
拉巴胺素 (一种mTORC1抑制剂) 有局限性,包括溶解性差和生物可用性差.

研究的目的:

开发和评估聚 (乳糖-co-甘油酸) 纳米颗粒 (Rapa-PLGA NPs) 用于增强在膀癌中的拉巴素输送.
研究Rapa-PLGANP在抑制膀癌细胞生长,迁移和克服耐药性的实验室疗效.

主要方法:

拉帕米辛被封装成聚 (乳酸-co-糖醇酸) 纳米颗粒 (Rapa-PLGA NPs).
使用Korsmeyer-Peppas模型分析了药物释放动力学.
在T24膀癌细胞上进行了体外细胞毒性,伤口愈合和基因表达分析.

主要成果:

拉帕-PLGANP显示持续的药物释放.
与自由拉巴胺相比,Rapa-PLGA NPs显著降低了IC50并抑制了癌细胞迁移.
基因表达分析显示mTOR,HIF-α,BCL-2和ABCC1的下调,FOXO1和MAPK的上调.

结论:

拉帕-PLGA NPs通过改善输送和调节关键基因来增强拉帕米对膀癌的治疗疗效.
这种纳米粒子系统在膀癌治疗中提供了一种有前途的策略,以克服药物耐药性.
需要进一步的体内研究来验证Rapa-PLGANP的治疗潜力.

更多相关视频

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...